Analysts are weighing in on how ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) , might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.1. The stock is rated as buy by 7 analysts, with 2 outperform and 1 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.
For the current quarter, the 9.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.49 a share, which would compare with $-0.39 in the same quarter last year. They have a high estimate of $-0.41 and a low estimate of $-0.58. Revenue for the period is expected to total nearly $80.00K from $1,000.00 the year-ago period.
For the full year, 9.00 Wall Street analysts forecast this company would deliver earnings of -1.70 per share, with a high estimate of $-0.99 and a low estimate of $-1.95. It had reported earnings per share of $-1.63 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $27.86M versus 61.00K in the preceding year.
The analysts project the company to maintain annual growth of around 73.60% percent over the next five years as compared to an average growth rate of 12.91% percent expected for its competitors in the same industry.
Among the 10 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for ACAD is $45.70 but some analysts are projecting the price to go as high as $54.00. If the optimistic analysts are correct, that represents a 61 percent upside potential from the recent closing price of $33.50. Some sell-side analysts, particularly the bearish ones, have called for $35.00 price targets on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) .
In the last reported results, the company reported earnings of $-0.39 per share, while analysts were calling for share earnings of $-0.33. It was an earnings surprise of -18.20%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimers disease psychosis. It also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.